Randomised double-blind placebo-controlled trial of 40 mg/day of Atorvastatin on reduction in severity of SEPSIS in ward patients

Heart of England Foundation Trust (UK)0 个研究点目标入组 414 人开始时间: 2007年1月4日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Aged more than 18 years
•2. Patients history suggestive of a new infection such as pneumonia, empyema, Urinary Tract Infection (UTI), meningitis, skin/soft tissue inflammation, acute abdominal infection, bone/joint infection, wound infection, catheter or device infection or endocarditis
•3. More than or equal to two of the following signs and symptoms of infection both present and new to the patient including:
•a. temperature more than 38°C or 36°C
•b. chills with rigors
•c. heart rate more than 90 beats per minute
•d. respiratory rate more than 20 bpm, or
•e. headache with stiff neck

•1. Signs of severe sepsis
•2. Known active liver disease, alcohol abuse or persistantly abnormal liver function tests
•3. Alanine aminotransferase more than two times the upper limit of normal laboratory ranges
•4. Creatine kinase more than three times the upper limit of laboratory normal ranges
•5. Pregnancy, breast feeding or women of child bearing potential not using adequate contraception
•6. Previous adverse reaction to statins
•7. Concomitant use of fibrates or other lipid lowering therapy
•8. Administration of Atorvastatin was ceased less than or equal to two weeks prior to the trial
•9. Concomitant use of erythromycin, telithromycin, clarithromycin, itraconazole, imidazoles, triazoles, cyclosporin or grapefruit juice
•10. Patients in another clinical trial
•11. Patients with terminal cancer
•12. Known ileus
•13. Failure to obtain written consent
•14. Inability to swallow tablets safely

发起方

Heart of England Foundation Trust (UK)